Compare PRME & BBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | BBCP |
|---|---|---|
| Founded | 2019 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.2M | 529.1M |
| IPO Year | 2022 | 2017 |
| Metric | PRME | BBCP |
|---|---|---|
| Price | $3.54 | $10.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $7.56 | ★ $8.25 |
| AVG Volume (30 Days) | ★ 2.4M | 165.6K |
| Earning Date | 05-08-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $4,632,000.00 | ★ $392,867,000.00 |
| Revenue This Year | $7.06 | $4.90 |
| Revenue Next Year | $47.01 | N/A |
| P/E Ratio | ★ N/A | $150.00 |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $2.67 | $5.56 |
| 52 Week High | $6.94 | $12.19 |
| Indicator | PRME | BBCP |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 63.56 |
| Support Level | $3.16 | $10.39 |
| Resistance Level | $3.69 | $11.15 |
| Average True Range (ATR) | 0.25 | 0.44 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 51.13 | 75.57 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.